LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various conditions including endometriosis, uterine fibroids, and central precocious puberty.
AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in
Canada.
Advanced prostate cancer can have a devastating impact on patients and their quality of life. As a physician, I am pleased to know that my patients will be able to access a treatment that helps reduce the administration burden many often experience. This announcement marks a significant advancement in how we treat and manage advanced prostate cancer for years to come.
says Dr. Andrew Loblaw, Clinician Scientist and Head of Genitourinary Radiation Oncology Clinical Studies Group.
Prostate cancer is the most prevalent cancer among Canadian men, representing one in five new cancer case diagnoses. Statistically, one in eight Canadian men will develop prostate cancer during their lifetime. Despite its high prevalence, most cases are treatable, especially when caught early. Given the significant impact on men's health, it is critically important to continually advance and introduce new treatment options, ensuring better outcomes and improved quality of life for patients.
At AbbVie, we strive to have a remarkable impact on people’s lives. With over three decades of improving the lives of Canadians living with advanced prostate cancer, this announcement reflects our longterm commitment to putting patients first and creating possibilities for communities.
says Rami Fayed, Vice President and General Manager of AbbVie Canada.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.